Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Hetero Labs Limited is a global pharmaceutical company that focuses on the development and manufacturing of generic and branded pharmaceutical products. It offers a wide range of products in areas such as anti-retrovirals, oncology, and cardiovascular therapies, serving healthcare providers and patients in over 125 countries while driving accessibility and affordability in healthcare.
Hetero Labs Limited, is an unlisted public company incorporated on 10 March, 1989. It is classified as a public limited company and is located in , Telangana. It's authorized share capital is INR 320.00 cr and the total paid-up capital is INR 277.06 cr.
Read more
** All rupee values in INR crores. Based on March 2024 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
** Delivery timelines are on best-effort basis during working hours. Filings 3-4 hours. Reports 24-48 hours.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
| State | Type | Address |
|---|
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Srinivas Reddy Male | 00016085 | 17 years |
| Whole-time Director | Venkatanarasa Reddy Attunuri | 00023432 | 12 years |
| Whole-time Director | Mohana Reddy Chilukuri | 00208921 | 26 years |
| Managing Director | Bandi Vamsikrishna
Shareholder
|
01014619 | 18 years |
| Director | Parthasaradhi Reddy Bandi
Shareholder
|
00015899 | 5 years |
| Additional Director | Vasudevan Sujesh | 08240092 | 2 years |
| Director | Govindaraju Bhavani | 09657046 | 2 years |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | 6,975.3 | 10,215.8 | 9,663.1 | 10,621.9 | 10,597.3 |
| Operating profit | 959.1 | 1,942.6 | 1,397.4 | 1,700.6 | 1,762.0 |
| Net profit | 563.1 | 1,225.6 | 825.6 | 914.8 | 782.1 |
| Gross margin | 38.5 | 42.9 | 38.8 | 40.3 | 43.5 |
| Operating margin | 13.8 | 19.0 | 14.5 | 16.0 | 16.6 |
| Net margin | 7.8 | 11.9 | 8.4 | 8.4 | 7.3 |
| Networth | 5,242.4 | 6,482.8 | 7,296.8 | 8,199.6 | 8,967.3 |
| Borrowings | 3,431.5 | 3,090.7 | 3,596.6 | 3,605.1 | 3,802.0 |
| Assets | 11,183.6 | 12,022.2 | 13,020.6 | 14,399.6 | 15,498.5 |
| Debt to equity | 0.7 | 0.5 | 0.5 | 0.4 | 0.4 |
| Current ratio | 1.4 | 1.6 | 1.5 | 1.6 | 1.6 |
| ROE | 10.7 | 18.9 | 11.3 | 11.2 | 8.7 |
| Days payable | 139.0 | 106.0 | 95.0 | 113.0 | 123.0 |
| WC days | 110.0 | 96.0 | 99.0 | 107.0 | 118.0 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 1.3 | 277.1 | 277.1 | 277.1 | 277.1 |
| Reserves | 5,241.0 | 6,205.7 | 7,019.8 | 7,922.6 | 8,690.2 |
| Borrowings + | 3,431.5 | 3,090.7 | 3,596.6 | 3,605.1 | 3,802.0 |
| Long term borrowings | 691.8 | 533.2 | 319.5 | 365.1 | 286.0 |
| Short term borrowings | 2,739.7 | 2,557.5 | 3,277.1 | 3,240.0 | 3,515.9 |
| Trade payables + | 1,637.5 | 1,694.3 | 1,545.9 | 1,966.2 | 2,020.7 |
| Days payable | 139.0 | 106.0 | 95.0 | 113.0 | 123.0 |
| Other liabilities + | 2,509.8 | 2,448.8 | 2,127.2 | 2,594.9 | 2,729.2 |
| Other non-current liabilities | 419.5 | 366.9 | 369.2 | 378.3 | 415.6 |
| Other current liabilities | 452.8 | 387.6 | 212.0 | 250.3 | 292.9 |
| Total liabilities | 11,183.6 | 12,022.2 | 13,020.6 | 14,399.6 | 15,498.5 |
| Fixed Assets + | 2,275.4 | 2,337.2 | 2,722.7 | 3,010.8 | 3,112.4 |
| Tangible assets | 2,091.4 | 2,084.8 | 2,279.7 | 2,453.6 | 2,652.6 |
| CWIP | 46.7 | 122.1 | 182.2 | 305.0 | 185.7 |
| Intangible assets | 137.3 | 130.2 | 260.9 | 252.2 | 274.1 |
| LT loans and advances | 812.7 | 800.4 | 868.5 | 1,021.4 | 1,251.2 |
| Other non-current assets | 1,166.6 | 1,554.7 | 1,777.2 | 1,789.0 | 1,874.5 |
| Current assets + | 6,928.9 | 7,329.9 | 7,652.2 | 8,578.3 | 9,260.3 |
| Inventories | 2,730.2 | 3,052.6 | 3,280.1 | 3,730.7 | 4,294.4 |
| Trade receivables | 3,626.0 | 3,756.2 | 3,887.4 | 4,013.2 | 4,062.6 |
| Cash and cash equivalents | 14.9 | 40.6 | 44.9 | 301.2 | 279.8 |
| ST loans and advances | 19.5 | 27.9 | - | - | - |
| Other current assets | 538.3 | 452.7 | 439.9 | 533.3 | 623.4 |
| Total assets | 11,183.6 | 12,022.2 | 13,020.6 | 14,399.6 | 15,498.5 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | 6,975.3 | 10,215.8 | 9,663.1 | 10,621.9 | 10,597.3 |
| Sales growth % | 5.15 | 46.46 | -5.41 | 9.92 | -0.23 |
| Expenses + | 6,518.3 | 8,670.2 | 8,618.6 | 9,455.8 | 9,411.4 |
| Cost of goods | 4,290.1 | 5,834.6 | 5,915.2 | 6,338.5 | 5,989.5 |
| Employee cost | 675.3 | 799.0 | 872.8 | 996.6 | 1,091.6 |
| Other costs | 1,050.9 | 1,639.6 | 1,477.6 | 1,586.2 | 1,754.2 |
| Operating profit + | 959.1 | 1,942.6 | 1,397.4 | 1,700.6 | 1,762.0 |
| Operating margin % | 13.8 | 19.0 | 14.5 | 16.0 | 16.6 |
| Other income | 246.6 | 89.9 | 157.9 | 223.1 | 154.1 |
| Interest | 313.2 | 210.3 | 155.6 | 326.0 | 337.3 |
| Depreciation | 188.9 | 186.7 | 197.2 | 208.6 | 238.8 |
| Exceptional items | - | - | - | - | -120.6 |
| Profit before tax | 703.7 | 1,635.4 | 1,202.4 | 1,389.1 | 1,219.3 |
| Tax | 140.6 | 409.8 | 376.8 | 474.4 | 437.3 |
| Profit - disc. ops | - | - | - | - | - |
| Net profit | 563.1 | 1,225.6 | 825.6 | 914.8 | 782.1 |
| Net margin % | 7.8 | 11.9 | 8.4 | 8.4 | 7.3 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | 0.7 | 0.5 | 0.5 | 0.4 | 0.4 |
| Net Debt/Equity | 0.7 | 0.5 | 0.5 | 0.4 | 0.4 |
| Total Debt/Assets | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 |
| Total Assets/Equity | 2.1 | 1.9 | 1.8 | 1.8 | 1.7 |
| Liquidity + | |||||
| Current Ratio | 1.4 | 1.6 | 1.5 | 1.6 | 1.6 |
| Quick Ratio | 0.9 | 0.9 | 0.9 | 0.9 | 0.8 |
| Interest Coverage | 3.1 | 9.2 | 9.0 | 5.2 | 5.2 |
| Performance | |||||
| Gross Margin | 38.5 | 42.9 | 38.8 | 40.3 | 43.5 |
| Operating Margin | 13.8 | 19.0 | 14.5 | 16.0 | 16.6 |
| Net Margin | 7.8 | 11.9 | 8.4 | 8.4 | 7.3 |
| Return + | |||||
| Return on Equity | 10.7 | 18.9 | 11.3 | 11.2 | 8.7 |
| Pre-tax ROCE | 17.6 | 34.9 | 22.5 | 24.3 | 23.3 |
| Return on Assets | 5.0 | 10.2 | 6.3 | 6.3 | 5.0 |
| Pre-tax ROIC | 8.9 | 18.4 | 11.1 | 13.0 | 12.2 |
| Efficiency + | |||||
| Days Payable | 139.0 | 106.0 | 95.0 | 113.0 | 123.0 |
| Days Inventory | 232.0 | 191.0 | 202.0 | 215.0 | 262.0 |
| Days Receivable | 190.0 | 134.0 | 147.0 | 138.0 | 140.0 |
| Fixed Asset Turnover | 3.1 | 4.4 | 3.5 | 3.5 | 3.4 |
| Total Asset Turnover | 0.6 | 0.8 | 0.7 | 0.7 | 0.7 |
| Working Capital | |||||
| Cash Conversion Cycle | 283.0 | 219.0 | 254.0 | 240.0 | 279.0 |
| Working Capital Days | 110.0 | 96.0 | 99.0 | 107.0 | 118.0 |
IDBI Trusteeship Services Limited
No. of Loans: 1
Total Amount : 4,990.0 cr
State Bank of India
No. of Loans: 5
Total Amount : 1,200.4 cr
Union Bank of India
No. of Loans: 1
Total Amount : 515.0 cr
Mahindra and Mahindra Financial Services Limited
No. of Loans: 47
Total Amount : 24.5 cr
Bank of India
No. of Loans: 47
Total Amount : 4.8 cr
Sundaram Finance Limited
No. of Loans: 1
Total Amount : 0.1 cr
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Camber Pharmaceuticals Inc | United States | - | - |
| Hetero Singapore PTE Ltd | Singapore | - | - |
| Camber Consumer Care Inc | United States | - | - |
| Hetero Australia PTY LTD | Australia | - | - |
| Hetero Labs Nigeria Limited | Nigeria | - | - |
| DMN Invest LLC | Russian Federation | - | - |
| Makiz Pharma LLC | Russian Federation | - | - |
| HETERO WIND POWER (PENNAR) PRIVATE LIMITED | Telangana | 2015 | ₹ 65.0 Cr |
| Hetero FZCO | United Arab Emirates | - | - |
| JSW WIND POWER (ISAPUR) LIMITED | Telangana | 2007 | ₹ 32.2 Cr |
| HETERO WIND POWER LIMITED | Telangana | 2010 | ₹ 154.0 Cr |
| ASPIRO PHARMA LIMITED | Telangana | 2014 | ₹ 404.1 Cr |
| Hetlabs Mexico S.A. DE C.V | Mexico | - | - |
| Akar Columbia SAS | Colombia | - | - |
| Hetero Kenya Limited | Kenya | - | - |
| Hetero Malta Limited | Malta | - | - |
| Excellan Peru SAC | Peru | - | - |
| Camber Pharma Mexico S A De C V. | Mexico | - | - |
| Hetero Philippines Inc. | Philippines | - | - |
| HETERO WIND POWER (ANANTA) PRIVATE LIMITED | Telangana | 2015 | ₹ 25.0 L |
| HETERO WIND POWER (RAYALA) PRIVATE LIMITED | Telangana | 2015 | ₹ 50.0 L |
| Pharmed Healthcare Company SAE | Egypt | - | - |
| Hetero (Thailand) Limited | Thailand | - | - |
| ANNORA PHARMA PRIVATE LIMITED | Telangana | 2015 | ₹ 286.0 Cr |
| WALLET PHARMA PRIVATE LIMITED | Telangana | 2015 | ₹ 98.0 Cr |
| EVARIC PHARMA PRIVATE LIMITED | Telangana | 2015 | ₹ 1.0 L |
| HETERO BIOTECH LIMITED | Telangana | 2004 | ₹ 5.0 L |
Read more
The incorporation date of HETERO LABS LIMITED is 10 March, 1989
The authorized share capital of HETERO LABS LIMITED is INR ₹ 320.0 Cr.
The paid-up capital of HETERO LABS LIMITED is INR ₹ 277.1 Cr.
The registered address of HETERO LABS LIMITED is #7-2-A2, Industrial Estate, Sanath Nagar, Sanathnagar I E, Hyderabad, Balanagar, Telangana, India, 500018 - 500018
The CIN number of HETERO LABS LIMITED is U24110TG1989PLC009723.